Typical Phase 1 oncology studies have changed and evolved as new techniques have developed, and target therapies have begun to reach the market. By looking at the types of drugs used, the dose levels tested and the patient populations focused on, it is possible to see where the current emphasis lies, and where unmet needs remain.